BOSTON--(BUSINESS WIRE)--March 6, 2006--Point Therapeutics, Inc. (NASDAQ:POTP) announced on Saturday, March 4, 2006 at the Keystone Symposium in Santa Fe, New Mexico, that the Company's investigational DPP-4 inhibitor for the treatment of type 2 diabetes, PT-630, improved glucose handling, insulin secretion and active GLP-1 levels in several rodent models of diabetes. The study treatment effects of PT-630 were greater than that of metformin, a commonly used drug to treat type 2 diabetes and a cyanopyrrolidine (CP), a DPP-4 inhibitor currently in clinical development to treat type 2 diabetes. All three agents were compared by chronic administration (44 days) in Zucker Diabetic Fatty rats.
